PubMed Health⌕ Search

Biomedical subjects

M G Plescia

Publications and source records attributed to M G Plescia.

2 recordsLinked to original sources

The Landau reaction: a clinical and electromyographic analysis.

Thirty normal infants aged two months (N=10), five months (N=11) and eight months (N=9) participated in a three-month longitudinal study of the Landau reaction. Each infant's response to horizontal suspension was filmed and electromyographically recorded. Thoraco-lumbar extension and head elevation 90 degrees above the horizontal (face vertical to the horizontal) were present in 45 per cent of infants at four months and in 90 per cent of infants between five and 10 months. The postural response changed little between five and ten months of age. Less than 10 per cent of the infants regressed in postural response between monthly examinations. No infant hung limply over the examiner's hand, and electromyographic activity of the neck extensors never decreased to zero. All infants were able to reassume neck and spinal extension following active and passive flexion of the neck. Kicking activity was observed in 80 per cent of infants over four months of age. A pattern of motor responses for the normal infant was noted and variations from this pattern which have been observed in infants with motor dysfunction are discussed. The EMG recordings correlated well with the visual observations and provided an accurate written record of the responses. They proved to be a reliable research tool in the study of infants' gross motor responses.

Electromyography↗

Mifepristone (RU 486): current knowledge and future prospects.

Mifepristone (RU 486) has received recent attention for its effects as an abortifacient. Mifepristone has not yet been approved for use in the United States. The Food and Drug Administration issued an "approvable letter" in September 1996, but mifepristone will not be available in the United States until a new manufacturer is found. Experience with mifepristone is extensive in Europe, and there have been retrospective studies and large, controlled clinical trials of its efficacy. It is most efficacious when administered to women who are less than 8 weeks pregnant, in a single 600-mg oral dose followed 48 hours later by administration of intravaginal misoprostol. This regimen has a success rate of 98%, as do most surgical abortive procedures. The most frequent adverse effect is painful contractions, which occur in up to 93% of women, with oral analgesia required in as many as half the cases. Large-scale surveys of women who elected medical abortion reported high patient satisfaction. Mifepristone is likely to have additional clinical uses. Researchers are exploring mifepristone's potential uses in cervical ripening and labor induction; contraception; delivery after intrauterine demise; treatment of breast cancer, unresectable meningioma, and prostate cancer; amelioration of endometriosis; and management of Cushing syndrome.

Abortifacient Agents, Steroidal↗